ABSTRACT-IL-17 is a cytokine produced by a newly identified T-cell subpopulation (T H 17/T ). It is a central mediator in inflammatory processes that connects T-cell stimulation with neutrophil mobilization. The role of IL-17 in the immune dysfunction after polytrauma is still not clarified. In a retrospective study, the systemic concentration of IL-17 and IL-6 of 71 polytraumatized patients were analyzed daily by enzyme-linked immunosorbent assay. The patients' collective consist of 55 men and 16 women (43 T 16 years; injury severity score, 33 T 13). In only 6% of the patients, an increase in systemic IL-17 was detected. In most patients (94%), no systemic IL-17 was detectable or the IL-17 concentrations in plasma were in the range of the healthy donor group. To identify a possible role of systemic IL-17 in the posttraumatic phase, the patients were divided into two groups. Group A (47 men, 15 women) consists of patients with IL-17 concentrations in the range of normal healthy donors. Group B (8 men, 1 woman) consists of patients with elevated (945 pg mL j1 on at least 3 consecutive days) systemic IL-17 concentrations. Three patients in group B showed highly increased systemic IL-17 concentrations (median, 9200 pg mL j1 ). These patients were male and showed all blunt chest and abdominal trauma with lung contusion and pneumohemothorax. However, there was no conformity in other injury patterns, injury severity score, age, outcome, intensive care period, or clinical complications. After a period of 4 years, we were able to obtain a new blood sample from one patient with high IL-17 level. The systemic IL-17 value of this former patient was now less than the detection limit. However, stimulation of peripheral blood mononuclear cells from this patient revealed elevated numbers of cells with the capacity to produce IL-17 as determined by enzyme-linked immuno spot assay and flow cytometry compared with peripheral blood mononuclear cells obtained from current polytrauma patients and healthy donors. In conclusion, IL-17 is not suitable as a pathophysiological or predictive marker after polytrauma. Whether highly increased systemic IL-17 concentrations detected in single patients are due to individually increased numbers of T H 17 cells as we have demonstrated with one rerecruited patient has to be further analyzed.
INTRODUCTION
IL-17 is a homodimeric cytokine of approximately 32 kd and is the prototype member of a cytokine family that is generally thought to increase inflammation by recruiting other immune cells to peripheral tissue. IL-17 is a proinflammatory cytokine that induces multiple other proinflammatory mediators, including chemokines, cytokines, and metalloproteases from epithelial, endothelial, and fibroblastic cells. IL-17 also stimulates epithelial, endothelial, or fibroblastic cells to secrete IL-6, IL-8, granulocyte colony-stimulating factor and prostaglandin E2. IL-17 is secreted by a subgroup of activated CD4 + T cells (T H 17/T ) and binds to a receptor that is expressed widely in the body but apparently more abundant in the spleen and kidneys (1) . T H 17 cells have been identified as a unique subset of T H cells that develops along a pathway that is distinct from the T H 1 and T H 2 cell differentiation (2) . The hallmark effector molecules of T H 1 and T H 2 cells, for example, interferon + and IL-4, have each been found to negatively regulate the generation of these T H 17 cells, as was also reported for IL-12 (3, 4) . IL-17 expression is initiated by transforming growth factor " signaling together with IL-6 and other proinflammatory cytokines. Maintenance and survival of T H 17 cells are dependent on IL-23 (5) . In the presence of IL-17, fibroblasts can sustain the proliferation of CD34 + hematopoietic progenitors and induce maturation into neutrophils. The role of IL-17 in various inflammatory processes is presently investigated. Recent studies have suggested that T H 17 cells have a dominant role in provoking chronic autoimmune inflammation of the central nervous system and joints (6) . The role of systemic IL-17 concentrations in response to severe injuries is still unknown. Our hypothesis was that systemic IL-17 of polytraumatized patients correlates with outcome or clinical parameters.
MATERIALS AND METHODS
We studied IL-17 and for comparison IL-6 plasma levels in 71 multiple injured patients (55 men, 16 women) with an average age of 43 T 16 years (range, 17Y82 years) and an average injury severity score (ISS) of 33 T 13 (range, 16Y66 years) admitted to the surgical intensive care unit of the trauma center (Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH, Ruhr-University Bochum, Germany). The mortality rate was 11.4% (n = 16; Table 1 ). The control group consisted of normal healthy volunteers (n = 25; mean age, 35 years; 7 men, 18 women). All patients were directly admitted from the site of the accident except for 7 patients (group A) who were admitted within 4 days after trauma from a secondary hospital. In addition, leukocyte cell counts and C-reactive protein (CRP) were determined in the routine laboratory program. This study was approved by our Institutional Human Use Committee and informed consent was obtained.
Plasma samples from patients and normal healthy donors were collected daily between 7 and 8 am together with routine blood collection (2.7 mL EDTAMonovette; Sarstedt, Nümbrecht, Germany). Blood samples from patients and the control group were processed identically within 30 min after withdrawal. After centrifugation of the blood, plasma was aliquoted and stored at j80-C until the cytokines were determined by enzyme-linked immunosorbent assay (ELISA).
ELISA system
Antibodies (capture and detection antibodies) and recombinant human cytokines (standards) were supplied by R&D Systems (Wiesbaden, Germany). Volumes of 100 2L were used throughout ELISA procedures except 200 2L for blocking solution (phosphate-buffered saline [PBS]/containing 1% bovine serum albumin) and washing buffer (PBS/0.05% Tween 20) . Cytokines were quantitated following the manufacturer's ELISA protocol. Enzyme-linked immunosorbent assay microtiter plates were read by an ELISA reader (MRX Revelation; Dynex Technologies, Chantilly, Va) set to 450 nm. The minimal standard concentration for IL-17 was 8 pg/mL and 36 pg/mL for IL-6. IL-17 from 25 healthy controls were 4 more than this concentration. Therefore, a threshold value of 45 pg/mL IL-17 was chosen because it represents the maximal IL-17 concentration measured in healthy donor plasma.
Isolation of peripheral blood mononuclear cell
Peripheral blood mononuclear cells (PBMCs) were isolated using the Becton Dickinson Vacutainer CPT cell preparation tube system with heparin as anticoagulant (BD-Biosciences, Heidelberg, Germany). After centrifugation (1,800g, 30 min, room temperature), red blood cells and granulocytes passed through the polyester gel to the bottom of the tube, whereas the PBMC and plasma remained above the polyester gel. The PBMC layer was carefully aspirated and transferred to a separate 50-mL tube that was subsequently filled with PBS (Sigma-Aldrich, St. Louis, Mo). After a 2-fold washing with PBS, the PBMCs were adjusted to 1 Â 
Enzyme-linked immuno spot assay
The amount of human IL-17 secreting cells in the freshly isolated PBMC fraction was analyzed by the IL-17 enzyme-linked immuno spot assay (ELISpot; R&D Systems) assay, which detects IL-17Ysecreting cells at the single cell level. In a polyvinylidene difluoride microplate precoated with polyclonal IL-17Yspecific antibodies, 2 Â 10 5 isolated PBMCs (RPMI 1640 0.2 mL j1 ) were added. Subsequently, the cells were stimulated with ionomycin (1 2g mL j1 ; SigmaAldrich) and phorbol myristate acetate (PMA; 10 ng mL j1 ; Sigma-Aldrich), and the microplate was placed into a humidified 37-C and 5% carbon dioxide incubator overnight. After washing, a biotinylated polyclonal antibody specific for human IL-17 was added. After a further wash step to remove any unbound biotinylated antibody, alkaline-phosphatase conjugated to streptavidin was added. Unbound enzyme was subsequently removed by washing, and a substrate solution (5-bromo4-chloro-3-indolyl phosphate and nitroblue tetrazolium) was added. A blueblack colored precipitate forms at the sites of cytokine localization and appears as spots, with each individual spot representing an individual IL-17Ysecreting cell. The developed well was analyzed by calculating the blue-black colored area of the precipitate by digital image analysis. The wells were microscopically photographed using a macro zoom system microscope (MVX10 MacroView; Olympus, Hamburg, Germany) and a digital camera (F-View II, Olympus). Images were processed using Cell P imaging software 2.3 (Olympus) and Photoshop 5.0 software (Adobe, UnterschleiQheim, Germany).
Intracellular cytokine analysis
Peripheral blood mononuclear cells (1 Â 10 6 cells mL j1 supplemented RPMI 1640) were stimulated with ionomycin (1 2g mL j1 ) and PMA (10 ng mL j1 ) in the presence of BrefeldinA (10 2g mL j1 ; Sigma-Aldrich) for 24 h in a humidified 37-C and 5% carbon dioxide incubator. Under these conditions, IL-17 accumulated in the cells and was detected using flow cytometry (FACSCalibur; BDBiosciences). Fluorescence data were analyzed using CELLQuest 1.2.2 (BD-Biosciences). Calibration reagents and solutions for flow cytometry were from BD-Biosciences. For each analysis, 10,000 cells were acquired. Fluorescencelabeled antibodies directed against IL-17 were from NatuTec (Frankfurt, Germany) and against CD3 from BD-Biosciences. Regions of positive fluorescence were determined by respective isotype control antibodies. Fluorescence signals of the isotype controls were adjusted as negative for 99% of gated cells. A scattergram region (forward scatter/side scatter) was set to gate the lymphocytes. Fluorescence values were expressed as mean fluorescence intensity.
Statistical analysis
Cytokine values from healthy donors versus trauma patients and among respective patients' subgroups were compared using the nonparametric MannWhitney U test. Correlations were calculated using the Spearman correlation. We considered P G 0.05 to be significant. SPSS 14.0 software (SPSS Inc., Chicago, Ill) was used.
RESULTS
In 71 polytraumatized patients (Table 1) , plasma concentration of IL-17 was analyzed daily during the intensive care period (876 samples). However, an increase in systemic IL-17 values that extended to more than healthy donor levels of IL-17 could be detected in only 6% of the patients (n = 9). In most patients (94%; n = 62), no IL-17 was detectable, or concentrations of IL-17 were in the range of the healthy donor control group.
Systemic IL-17 analyzed by ELISA
To identify a possible role of systemic IL-17 in the posttraumatic phase, the patients were divided into two groups according to the IL-17 concentrations measured. Group A consists of patients with no detectable IL-17 or IL-17 concentrations in the range of the healthy donor control group. Group B is composed of patients whose systemic IL-17 concentrations were more than the value of 45 pg/mL for at least 3 consecutive days ( Table 1, Fig. 1) . A threshold value of 45 pg/mL IL-17 was chosen because it represents the maximal IL-17 concentration measured in healthy donor plasma ( Table 1) . Periods of at least 3 consecutive days with elevated concentrations of IL-17 have been analyzed at different periods after trauma and showed no common pattern. Systemic IL-17 concentrations in group A (median, 0.5 pg mL j1 ; range, 0 Y 238 pg/mL; P = 0.73) were not significantly different compared with IL-17 concentrations of normal healthy donors (n = 25; median, 0 pg mL j1 ; range, 0Y45 pg mL j1 ). Because of the preselection used (see above), IL-17 concentrations of patients in group B (median, 75 pg mL j1 ; range, 8Y1,822 pg mL j1 ) were significantly elevated compared with values of normal donors (P e 0.001; Fig. 1) .
In contrast to IL-17, levels of IL-6 in groups A (median, 12 pg mL j1 ; range, 2Y2,572 pg mL j1 ) and B (median, 40 pg mL j1 ; range, 4Y708 pg mL j1 ) are both significantly increased (groups A and B P e 0.001) compared with IL-6 concentrations of healthy normal donors (median, 6.6 pg mL j1 ; range, 3Y16 pg mL j1 ; Fig. 1 ). Within group B, only a minor correlation between systemic IL-17 and systemic IL-6 (r = 0.258; P G 0.05) and no correlation between systemic IL-17 and CRP values (r = 0.016; P = 0.865) or leukocyte counts (r = 0.177; P = 0.066) were observed. Systemic IL-6 concentrations in group B are significantly increased compared with IL-6 in group A (Table 2 ; P e 0.001), although there were comparable median leukocyte counts and CRP values ( Fig. 1 and Tables 2  and 3 ).
Characteristics of patients in group B
In group B patients, the injury severity correlated negatively with plasma levels of IL-17. As shown in Figure 2 , patients with an ISS of 25 or less showed significant higher values of IL-17 (n = 4; 52 samples) compared with patients with an ISS greater than 25 (n = 5; 58 samples; P e 0.001). The patients in group B with an ISS of 25 or less also have significantly increased IL-6 concentrations (P e 0.001) and leukocyte values (P e 0.001) compared with IL-6 concentrations and leukocyte values in patients with a ISS greater than 25 (Fig. 2, Table 2 ). C-reactive protein values of patients with an ISS of 25 or less and patients with an ISS greater than 25 were not different (P = 0.404; Tables 2 and 3) . Nonsurvivors (n = 3; 43 samples) in group B revealed significantly increased IL-6 concentrations ( Fig. 2 ; P e 0.001) and CRP values (Table 2 ; P e 0.001) compared with IL-6 concentrations and CRP values in survivors (n = 6; 67 samples). In contrast, IL-17 concentrations (Fig. 2) and leukocyte values showed no differences in nonsurvivors and survivors in group B (Tables 3 and 4) .
In group B, three patients with systemic IL-17 concentrations beyond the value of 200 pg/mL on at least 3 days (median, 245.9 pg mL j1 ) were detected. These patients were analyzed in more detail in clinical course ( Table 4 ). The patients were men and showed all blunt chest and abdominal trauma with lung contusion and pneumohemothorax. However, there was no conformity in other pattern of injuries, ISS, age, outcome, intensive care period, or clinical complications. One of these patients (male; 38 years; ISS, 25; Table 4 patient 3) died due to multiorgan failure after 80 days' intensive care. Further injuries of this patient were unstable pelvic ring fracture, femur shaft fracture, proximal tibia fracture, secondary cholangitis, and craniocerebral trauma. In plasma samples (n = 25) of this patient, the highest IL-17 concentrations (median, 267 pg mL j1 ; range, 34Y1,053 pg mL j1 ) were measured.
The two other patients (21 years; ISS, 34; Table 4 patient 1  and 47 years; ISS, 16; Table 4 patient 2) survived after an intensive care period of 27 and 32 days, respectively. The measured median IL-17 values of these patients are 253 (range, 169Y298 pg mL j1 ) and 203 pg mL j1 (range, 73Y1,822 pg mL j1 ). Further injuries of patient 1 were an odontoid fracture (Anderson type III), a dislocated spine fracture with complete paraplegia, and splenic rupture (comorbidity smoking). Further injuries of patient 2 were a sternal fracture, dissection of the abdominal aorta, rupture of the small bowel, and a calcaneal fracture (Table 4) .
ELISpot and flow cytometry
We were able to obtain a blood sample from one single patient (patient 2) (one succumbed to his injuries, one was not tracked down after that time) of those survivors who showed high IL-17 levels posttrauma. The period between trauma and new investigation was 4 years. The systemic IL-17 value was actually less than the detection limit. Now, we additionally stimulated freshly isolated PBMC from this patient (patient 2; group B) and detected elevated areas (39.4%) of antiYIL-17 immuoreactivity that reflects an elevated number of IL17Yreleasing cells in ELISpot analysis (Fig. 3A) . This value 
DISCUSSION
The present study demonstrates that a minority of polytrauma patients have elevated systemic IL-17 concentrations. Haznedaroglu et al. (7) reported IL-17 plasma levels of 40 T 2 pg/mL, and Hashmi and Zeng (8) reported 257 T 71 pg/mL in healthy normal volunteers. Indeed, both used different commercial ELISA kits for determining the systemic IL-17 levels. Overexpression of IL-17 has been found to be associated with several inflammatory diseases, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and asthma (9) . IL-17 is believed to contribute to the pathogenesis of these diseases as a potent proinflammatory mediator (9Y11). Kotake et al. (12) found elevated levels of IL-17 in synovial fluid from patients with rheumatoid arthritis in contrast to synovial fluid from patients with osteoarthritis. Kim et al. (13) found a significantly higher IL-17 production in stimulated PBMCs from patients with rheumatoid arthritis than in those from patients with osteoarthritis and control incubation.
IL-17 is secreted primarily by T H 17 cells. T H 17 cell differentiation is regulated by the presences of transforming growth factor " and IL-6 (14) . In contrast, IL-23 seems to be an essential survival factor for T H 17 but is not required for their differentiation (5, 14, 15) . Local macrophages and dendritic cells rapidly release IL-23 after severe injury or during acute infection (6, 11, 15) . This promotes the survival of T H 17 cells and, in turn, the release of IL-17. IL-17 leads to neutrophil recruitment through the induction of granulocyte colony-stimulating factor and IL-8 (3, 16, 17) and by its ability to synergize with other proinflammatory cytokines (18) . Additionally, IL-17 increases the production of IL-6 that enhances the local inflammatory microenvironment (19) . Thus, it has been suggested that T H 17 cells are an important response to severe injuries that require immediate neutrophil recruitment to prevent tissue necrosis or sepsis (6) .
This study demonstrates no increase in systemic IL-17 concentrations during the intensive care period in most (94%) multiple injured patients. However, we have analyzed plasma IL-17 that gives no insights into local concentrations of IL-17.
Our data are not consistent with a recent report that plasma concentrations of IL-17 are correlated with plasma IL-6 concentrations. In patients with coronary artery disease or acute myocardial infarction, a correlation of IL-17 with IL-6 and CRP was demonstrated (8) .
Three male patients in group B showed highly increased systemic IL-17 concentrations. Their injury pattern includes blunt chest and abdominal trauma with lung contusion and pneumohemothorax. However, patients with low or no systemic IL-17 concentrations showed a similar injury pattern. Therefore, these injuries have obviously no effect on systemic IL-17 concentrations. Additionally, these patients have no conformity in further pattern of injuries, ISS, age, outcome, intensive care period, or clinical complications. Two of the three patients were treated with continuous venovenous hemofiltration during 11 and 20 days (Table 4 ). However, hemofiltration seems to have no influence on systemic IL-17 values because systemic IL-17 levels on days with hemofiltration were not different from IL-17 concentrations on days without hemofiltration. Significantly, the IL-17 values in patients with hemofiltration were more than IL-17 concentrations in patient 2 without hemofiltration.
Gene polymorphism might be a possible reason for an individual increase in cytokine production. Several studies focused on gene polymorphism in cytokines such as TNF-! as a potential risk factor (20) . Whether a genetic predisposition influences systemic IL-17 levels has been reanalyzed by the availability of a plasma sample obtained from one patient (patient 2; Table 4 ELISA results. Now, after recovery, this patient shows no increased systemic IL-17. However, after stimulation of freshly isolated PBMC from this patient, his cells responded again with a high production of IL-17, and more T H 17 cells were measured. Increased number of T H 17 cells was not due to an elevated number of CD3 + cells. Although these analyses have been investigated in one single patient, these results suggest a genetic disposition to generate higher systemic IL-17 levels under inflammatory conditions due to elevated numbers of T H 17 cells.
According to our study, the analysis of systemic IL-17 has no prognostic value after major trauma. The present data demonstrate elevated levels of systemic IL-17 in a minority of multiple injured patients that may be related to an individual predisposition. Whether there is a general genetic predisposition for an elevated IL-17 production after trauma or infection has to be analyzed by further studies.
